

**Amendments to the Claims:**

This listing of claims as required by 37 C.F.R. 1.121 will replace all prior versions and listing of claims in the application.

---

1. Cancelled.

2. Cancelled.

3. Cancelled.

4. Cancelled.

5. Cancelled.

6. Cancelled.

7. Cancelled.

8. Cancelled.

9. Cancelled.

10. Cancelled.

11. Cancelled.

12. Cancelled.

13. Cancelled.

14. Cancelled.

15. Cancelled.

16. Cancelled.

17. Cancelled.

18. (Twice-amended) A method for inducing an immune response in a mammal, including a human, the method comprising administering to the mammal a compound comprising a CpG dinucleotide and an immunomodulatory moiety, selected from the group consisting of one or more abasic nucleoside, 1,3-propanediol linker, which may be substituted or unsubstituted, 3'-3' linkage and modified base-containing nucleosides selected from the group consisting of inosine, 2-amino-purine, nebularine, 7-deaza-guanosine, nitropyrrole, nitroindole, deoxyuridine, 4-thio-deoxyuridine, d-isoguanosine, d-iso-5-methylcytosine and P-base; and wherein the compound has greater immunostimulatory effect than it would have if it lacked the immunomodulatory moiety.

19. (Original) The method according to claim 18, wherein the mammal is a human.

20. (Original) The method according to claim 18, wherein the administration of the compound is parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal, or intrarectal.

21. (Previously Amended) The method according to claim 18, wherein the compound is administered at a sufficient dosage to attain a blood level of oligonucleotide from about 0.01 micromolar to about 10 micromolar.

22. (Original) The method according to claim 18, wherein dosage of compound is from about 0.1mg per patient per day to about 200mg per kg body weight per day.

23. (Original) The method according to claim 18, wherein the compound is administered in combination with a vaccine.

24. (Previously Amended) The method according to claim 23, further comprising administering an adjuvant.

25. Cancelled

D  
concl'd

---

26. Cancelled.

27. (Currently Amended) The method according to claim 2518, wherein G is selected from the group consisting of guanosine, 7-deazaguanosine and inosine.